Author: Dr Daniel Haag

    Head of Neuroscience at Neucyte
    As the Head of Neuroscience and Co-founder, Dr. Daniel Haag drives the scientific direction of NeuCyte Inc. and leads the development of novel human neural in vitro platforms for neurotoxicity assessment and drug discovery.

    How SynFire® Technology can benefit your research

    In celebration of our distributorship with NeuCyte, REPROCELL catches up with NeuCyte’s Head of Neuroscience, Dr Daniel Haag, to discuss the benefits of SynFire technology. Read on to find out the science behind this technology, and how using human neural models can benefit your drug discovery and toxicology research.

    Continue reading